EUCTR2006-005032-25-GR进行中（未招募）不适用
A multi-centre phase II controlled study of Vx-001 in Non Small Cell Lung Cancer (NSCLC)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 225
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients have given written informed consent before any study related activities are carried out
- •Histologically documented unresectable stage III and IV NSCLC. All histological subtypes are acceptable. Cancer stage must be confirmed and documented by computer tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) scan or whole body radionuclear body scan.
- •Documented stable disease or objective response after primary chemotherapy or chemo-radiotherapy (minimum two cycles of platine-based or non-platine-based chemotherapy and a minimum radiation dose of = 50Gy) for unresectable stage III/IV disease.
- •Patients must have completed the primary chemotherapy or chemo-radiotherapy at least four weeks and no later than eight weeks before entering study.
- •WHO performance status 0-1
- •Neutrophils >1500/µl, lymphocytes >1000/µl, platelets >105/µl, Hgb >10g/dl
- •Male or female = 18 years of age
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Receipt of immunotherapy (interferons, interleukins, TNF, GM-CSF, G-CSF, M-CSF) within one month before entering study
- •A documented autoimmune or immunodeficiency disease.
- •Known HBV, HCV or HIV infections
- •Past or current history of neoplasm other than lung cancer, except for curatively treated non-melanoma skin cancer and in situ carcinoma of the cervix.
- •Hepatic dysfunction (ALT>2.5 times normal upper limit, AST>2.5 times normal upper limits, bilirubin=1.5 times normal upper limit.
- •Renal dysfunction (serum creatinine=2mg/dl)
- •Congestive heart failure, uncontrolled angina, uncontrolled hypertension, uncontrolled arrhythmia, myocardial infraction in the previous 6 months
- •Acute or chronic infectious disease
- •Pregnant or breast-feeding women
- •Simultaneous participation in another clinical study
- •Known alcohol/drug abuse
- •Requires concurrent treatment with a non-permitted drug.
研究者
相似试验
进行中（未招募）
不适用
A multi-center single arm phase II study of MDX-010 BMS-734016 monotherapy in patients with previously treated unresectable stage III or IV melanoma. - NDEUCTR2005-002051-41-ITBRISTOL-M.SQUIBB150
进行中（未招募）
不适用
A Multi-Center Single Arm Phase II Study of MDX-010 (BMS-734016) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV Melanoma.Revised Protocol 01, incorporating Amendment 02; and Pharmacogenetics Blood Sample Amendment #01, version 1.0 dated 01-Jul-05, Pharmacogenomics Archived Tissue Sample Amendment #03, version 1 dated 29-Mar-06 and Pharmacogenomic Biomarker Sample Amendment #04, version 1 dated 03-Apr-06.MelanomaEUCTR2005-002051-41-SEBristol-Myers Squibb International Corporation170
进行中（未招募）
不适用
A Multi-Center Single Arm Phase II Study of MDX-010 (BMS-734016) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV MelanomaRevised Protocol 01, incorporating Amendment 02Estudio multicéntrico, fase II, de un solo brazo de tratamiento con MDX-010 (BMS734016) en monoterapia en pacientes con melanoma Estadio III o IV previamente tratadoMelanomaEUCTR2005-002051-41-ESBristol-Myers Squibb International Corporation170
进行中（未招募）
1 期
A Multi-Center Single Arm Phase II Study of MDX-010 (BMS-734016) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV Melanoma.Revised Protocol 01, incorporating Amendment 02; and Pharmacogenetics Blood Sample Amendment #01, version 1.0 dated 01-Jul-05, Pharmacogenomics Archived Tissue Sample Amendment #03, version 1 dated 29-Mar-06 and Pharmacogenomic Biomarker Sample Amendment #04, version 1 dated 03-Apr-06.MelanomaEUCTR2005-002051-41-NOBristol-Myers Squibb International Corporation170
进行中（未招募）
不适用
A Multi-Center Single Arm Phase II Study of MDX-010 (BMS-734016) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV Melanoma.Revised Protocol 02, incorporating Amendment 06, Administrative Letter 01, 02, and 03; and Pharmacogenetics Blood Sample Amendment #01, version 1.0 dated 01-Jul-05, Pharmacogenomics Archived Tissue Sample Amendment #03, version 1 dated 29-Mar-06 and Pharmacogenomic Biomarker Sample Amendment #04, version 1 dated 03-Apr-06.MelanomaEUCTR2005-002051-41-ATBristol-Myers Squibb International Corporation170